RNAI THERAPIES FOR CEREBRAL ISCHEMIA
First Claim
1. A polymer nanocapsule comprising a polymer shell and a microRNA (miRNA) molecule, wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are novel methods of treating cerebral ischemia, comprising administering a polymer nanocapsule or a composition thereof. Said nanocapsules comprise a polymer shell and an RNAi (e.g., miRNA) molecule, wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer; and the RNAi molecule provides therapeutic benefits to a subject suffering from cerebral ischemia. Also disclosed herein are compositions of said polymer nanocapsules.
0 Citations
77 Claims
- 1. A polymer nanocapsule comprising a polymer shell and a microRNA (miRNA) molecule, wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer.
-
38. A method of treating cerebral ischemia, brain ischemia or reperfusion injury, comprising administering a polymer nanocapsule, wherein the polymer nanocapsule comprises a polymer shell and an RNAi molecule;
- wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer; and
the RNAi knocks down or decreases expression of an overexpressed gene and/or increases expression of a gene in which expression is otherwise reduced or inhibited, thereby treating the cerebral ischemia, brain ischemia or reperfusion injury. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)
- wherein the polymer shell comprises a) at least one positively charged monomer, b) at least one degradable cross-linker, and c) at least one neutral monomer; and
Specification